New Heart Program Saves Patients For Fertility Medications

Armen Hareyan's picture

Ferring Pharmaceuticals announced a new, improved cost-saving program for heart patients who are considering fertility treatment, but find the costs a challenge.


Ferring's HEART (Helping Expand Access to Reproductive Therapy) Program gives women greater access to fertility medications, saving them as much as $700 on two frequently prescribed fertility treatments. The expanded program now includes both BRAVELLE (urofollitropin for injection, purified) and ENDOMETRIN (progesterone) Vaginal Insert, 100 mg, a new Ferring product for progesterone supplementation, administered following treatment with BRAVELLE.

"In our ongoing effort to increase access to safe, effective fertility treatments, we have expanded our long-time HEART Program to give qualified couples a greater chance to build families," said Olivier Delannoy, Vice President, Infertility, at Ferring. "We believe that cost should not be a barrier to parenthood."

With Ferring's expanded HEART Program, patients can receive up to 10 vials of BRAVELLE free of charge as part of their prescription (for a minimum of 40 vials) and one free box (21 vaginal inserts) of ENDOMETRIN.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.